B
Bayhill Therapeutics
Bayhill Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for
About Bayhill Therapeutics
Bayhill Therapeutics, operating initially as Tolerion Inc., was a clinical-stage biopharmaceutical firm established in 2000 by Lawrence Steinman and Hideki Garren. The company focused on developing treatments for autoimmune diseases by leveraging its proprietary BHT-DNA therapeutic platform. This platform was designed to re-educate the immune system and restore its tolerance to self-antigens, selectively eliminating harmful immune responses without impacting the rest of the immune system. The business model centered on advancing its drug candidates through clinical trials and forming strategic partnerships with larger pharmaceutical companies for further development and commercialization.
The company's pipeline included several promising candidates. BHT-3009 was developed for multiple sclerosis and completed a Phase II trial. Another key asset, BHT-3021, targeted type 1 diabetes. This DNA-based immunotherapy, which encodes for human proinsulin, aimed to halt the autoimmune damage to the pancreas. A third candidate, BHT-3034, was developed for myasthenia gravis and received clearance for a Phase I/II clinical study.
Throughout its operation, Bayhill Therapeutics secured significant financing, raising a total of $138 million over six funding rounds from investors such as TriplePoint Capital, USVP, Morgenthaler Ventures, and Lilly Ventures. A major milestone was the exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development and commercialization of BHT-3021. This deal included an upfront payment of $25 million and potential milestone payments exceeding $325 million. Despite its clinical progress and successful fundraising, the company attempted an IPO in 2008 but had to withdraw due to unfavorable market conditions. Bayhill Therapeutics was ultimately dissolved in 2012.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2009 | $10M | $40M | Undisclosed | — |
| SERIES BEquity / VC | May 2005 | $35M | $142M | Latterell Venture Partners · Lilly Ventures · U.S. Venture Partners · Pappas Capital | — |
Growth signals
Latest recorded traffic for Bayhill Therapeutics is 0 monthly website visits. Bayhill Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bayhill Therapeutics in the Portola Valley ecosystem
The Bayhill Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
- MVMorgenthaler Ventures
- CVCMEA Ventures
U.S. Venture Partners
The Vertical Group
Latterell Venture Partners
Lilly Ventures- DVDeNovo Ventures
Pappas Capital- PAPac-Link
IQVIA- MPMontreux Equity Partners
Other known investors1 additional known investor
University of Miami
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bayhill Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bayhill Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










